Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 29477-83-6 Chemical Structure| 29477-83-6

Structure of Narciclasine
CAS No.: 29477-83-6

Chemical Structure| 29477-83-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Narciclasine is a plant growth modulator. Narciclasine modulates the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner.

Synonyms: Lycoricidinol; (+)-Narciclasine; NSC 266535

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Narciclasine

CAS No. :29477-83-6
Formula : C14H13NO7
M.W : 307.26
SMILES Code : O=C1N[C@@]2([H])[C@H](O)[C@H](O)[C@@H](O)C=C2C3=C1C(O)=C4C(OCO4)=C3
Synonyms :
Lycoricidinol; (+)-Narciclasine; NSC 266535
MDL No. :MFCD01729949

Safety of Narciclasine

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P264-P270-P301+P310-P321-P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Narciclasine

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT-29 0.032 μM (IC50) 72 hours Inhibited cell proliferation with IC50 of 0.032 μM PMC9496155
LoVo 0.023 μM (IC50) 72 hours Inhibited cell proliferation with IC50 of 0.023 μM PMC9496155
HCT-116 0.052 μM (IC50) 72 hours Inhibited cell proliferation with IC50 of 0.052 μM PMC9496155
Yeast strain SAN006 0.1 mM Assess cytotoxicity of sanguinarine PMC11282404
Ccd-25-Lu normal lung fibroblasts 1 μM 18 hours No marked apoptotic morphological changes induced PMC1993861
PC-3 prostate cancer cells 1 μM 18 hours Induced marked apoptotic morphological changes and loss of mitochondrial membrane potential PMC1993861
MCF-7 breast cancer cells 1 μM 18 hours Induced marked apoptotic morphological changes and loss of mitochondrial membrane potential PMC1993861
Tobacco BY-2 cells 0.5 and 5.0 μM 2 days To study the effects of NCS on cell cycle progression, results showed that NCS inhibits cell division and affects the expression of cell cycle genes. PMC3282671
HCC-1937 50 nM 24 h To evaluate the inhibitory effect of Narciclasine on HCC-1937 cell proliferation and its ability to induce autophagy-dependent apoptosis PMC6528917
MDA-MB-231 breast cancer cells 1 μM 24 hours Induced DNA laddering PMC1993861
MCF-7/TR cells 100 nM 24 hours Specifically degraded total STAT3 via the proteasome pathway PMC8783118
MCF-7 cells 100 nM 24 hours Suppressed phosphorylation, activation, dimerization, and nuclear translocation of STAT3 PMC8783118
IMG cells 50 nM 24 hours To evaluate the effect of Narciclasine on LPS-induced inflammatory response. Results showed that Narciclasine alone did not induce inflammatory response but exacerbated inflammation when combined with LPS. PMC10216802
BSC-1 cells 40-320 nM 24 hours To evaluate the inhibitory effect of Narciclasine on VACV viral protein expression in BSC-1 cells, showing a dose-dependent decrease in viral protein levels. PMC11894989
Huh7.5.1 cells 40-320 nM 24 hours To evaluate the cytotoxicity of Narciclasine on Huh7.5.1 cells, showing a slight reduction in cell viability starting from 80 nM. PMC11894989
36C15Q cells 20 nM 48 hours Promotes oxidative metabolism gene expression, reduces lipid accumulation PMC5331945
C2C12 cells 20 nM 48 hours Promotes oxidative metabolism gene expression, reduces lipid accumulation PMC5331945
CoN 1.1 μM (IC50) 72 hours Inhibited cell proliferation with IC50 of 1.1 μM PMC9496155
DLD-1 0.030 μM (IC50) 72 hours Inhibited cell proliferation with IC50 of 0.030 μM PMC9496155
HeLa cells 40-320 nM 24 hours To evaluate the cytotoxicity of Narciclasine on HeLa cells, showing no significant effect on cell viability at ≤320 nM. PMC11894989
Arabidopsis root tip cells 0.5 and 5.0 μM 6 to 48 hours To analyze the effects of NCS on the expression of core cell cycle genes, results showed that NCS disturbs the expression of G1/S and G2/M phase genes. PMC3282671
Neonatal rat cardiomyocytes (NRCMs) 0, 30, 100, and 300 nM To evaluate the effect of Narciclasine on LPS-induced inflammation in cardiomyocytes. Results showed that Narciclasine attenuated LPS-induced decrease in cell viability in a dose-dependent manner, suppressed inflammatory cytokine (TNF-α, IL-1β, and IL-6) release, and reduced apoptosis. PMC8221305

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced obesity model Oral gavage 1 mg/kg Weekly for seven consecutive weeks Attenuates obesity, promotes energy expenditure, improves metabolic parameters PMC5331945
BALB/c-nu mice MCF-7 xenograft model Intraperitoneal injection 1 mg/kg Every 2 days for 4 weeks Significantly reduced tumor size and weight, decreased STAT3 phosphorylation levels PMC8783118
BALB/c nude mice HCC1937 TNBC xenograft model Oral 2 or 5 mg/kg Three times per week for 21 days To evaluate the inhibitory effect of Narciclasine on HCC1937 TNBC xenograft tumor growth and its mechanism PMC6528917
BALB/C mice IMQ-induced psoriasis-like dermatitis model Intradermal injection 2mg/kg Once daily for 6 days To evaluate the therapeutic effect of Ncs on IMQ-induced psoriasis-like dermatitis, results showed that Ncs significantly improved skin lesions, reduced epidermal thickening and immune cell infiltration. PMC9869703
Arabidopsis Arabidopsis seedlings Medium treatment 0.1, 0.5, 1.0 and 5.0 μM Continuous treatment for 7 days To study the inhibitory effects of NCS on Arabidopsis root growth, results showed that NCS significantly inhibited root growth and lateral root density. PMC3282671
C57BL/6 mice LPS-induced acute myocardial injury model Gavage 0.1 mg/kg Once daily for 7 days To investigate the protective effect of Narciclasine on LPS-induced myocardial injury. Results showed that Narciclasine partly improved cardiac function parameters (e.g., LVEF and LVFS), increased survival rates, and reduced inflammatory indicators (e.g., MPO and cytokines IL-6, IL-1β, TNF-α, VEGF). PMC8221305
Sprague-Dawley rats LPS-induced neonatal acute lung injury model Subcutaneous injection 0.7 mg/kg Administered 12 hours prior to LPS exposure, lasting for 72 hours Narciclasine attenuated LPS-induced pathological injury and pulmonary edema, suppressed the secretion of inflammatory cytokines, alleviated oxidative stress and apoptosis, and exerted protective effects by inhibiting the activation of the TLR4/NF-κB/Cox2 signaling pathway. PMC8291818
Neonatal rats E. coli-induced sepsis model Intraperitoneal injection 0.1 mg/kg, 1 mg/kg, 3 mg/kg Administered 1 hour after sepsis induction, observed for 30 hours Narciclasine significantly reduced mortality in neonatal rats with sepsis, alleviated clinical sepsis symptoms, reduced bacterial load, decreased levels of inflammatory cytokines, inhibited the expression of S100A8/A9, alleviated inflammation and injury in liver and lungs, improved hematological parameters, and suppressed the activation of the NF-κB signaling pathway. PMC7031385

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.25mL

0.65mL

0.33mL

16.27mL

3.25mL

1.63mL

32.55mL

6.51mL

3.25mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories